Enliven Therapeutics, Inc.
US ˙ NasdaqGS ˙ US29337E1029

SecurityELVN / Enliven Therapeutics, Inc.
InstitutionBlackstone Group Inc
Latest Disclosed Ownership954,946 shares
Latest Disclosed Value $ 14,706,168
Blackstone Group Inc reports 27.69% decrease in ownership of ELVN / Enliven Therapeutics, Inc.

On February 17, 2026 - Blackstone Group Inc filed a 13F-HR form disclosing ownership of 954,946 shares of Enliven Therapeutics, Inc. (US:ELVN) valued at $14,706,168 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on May 15, 2026 disclosing 0 shares of Enliven Therapeutics, Inc.. This represents a change in shares of -27.69% during the quarter. The current value of the position is $33,891,034 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-17 2025-12-31 13F ENLIVEN THERAPEUTICS COM 29337E102 954,946 -365,646 -27.69 14,706 -45.60 0.0526
2026-05-15 2025-09-30 13F/A-1 ENLIVEN THERAPEUTICS COM 29337E102 0 -100.00 0
2025-11-14 2025-09-30 13F ENLIVEN THERAPEUTICS COM 29337E102 1,320,592 0 0.00 27,033 2.04 0.1088
2025-08-14 2025-06-30 13F ENLIVEN THERAPEUTICS COM 29337E102 1,320,592 558,285 73.24 26,491 76.58 0.1131
2025-05-15 2025-03-31 13F ENLIVEN THERAPEUTICS COM 29337E102 762,307 388,984 104.20 15,002 78.62 0.0623
2025-02-14 2024-12-31 13F ENLIVEN THERAPEUTICS COM 29337E102 373,323 0 0.00 8,400 -11.90 0.0382
2024-11-14 2024-09-30 13F ENLIVEN THERAPEUTICS COM 29337E102 373,323 52,143 16.23 9,535 27.04 0.0416
2024-08-14 2024-06-30 13F ENLIVEN THERAPEUTICS COM 29337E102 321,180 295,989 1,174.98 7,506 1,594.13 0.0314
2024-05-15 2024-03-31 13F ENLIVEN THERAPEUTICS COM 29337E102 25,191 25,191 443 0.0018
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.